Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer

[1]  L. Qin,et al.  Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition , 2018, Acta biochimica et biophysica Sinica.

[2]  Yi-Chuan Cheng,et al.  Glucose-6-phosphate dehydrogenase is indispensable in embryonic development by modulation of epithelial-mesenchymal transition via the NOX/Smad3/miR-200b axis , 2018, Cell Death & Disease.

[3]  Xianghuo He,et al.  MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway. , 2017, Cancer research.

[4]  Shivashankar H. Nagaraj,et al.  Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring. , 2017, The Biochemical journal.

[5]  A. Giatromanolaki,et al.  Metabolic cooperation between co-cultured lung cancer cells and lung fibroblasts , 2017, Laboratory Investigation.

[6]  H. Xie,et al.  PGK1 Drives Hepatocellular Carcinoma Metastasis by Enhancing Metabolic Process , 2017, International journal of molecular sciences.

[7]  T. Fan,et al.  Glycolytic reprogramming through PCK2 regulates tumor initiation of prostate cancer cells , 2017, Oncotarget.

[8]  S. Li,et al.  Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer , 2017, Clinical and Translational Oncology.

[9]  H. Levine,et al.  EMT and MET: necessary or permissive for metastasis? , 2017, bioRxiv.

[10]  M. Garg.  Epithelial, mesenchymal and hybrid epithelial/mesenchymal phenotypes and their clinical relevance in cancer metastasis , 2017, Expert Reviews in Molecular Medicine.

[11]  F. Bidard,et al.  Circulating tumor cells: clinical validity and utility , 2017, International Journal of Clinical Oncology.

[12]  Yuechun Zhu,et al.  Overexpression of G6PD Represents a Potential Prognostic Factor in Clear Cell Renal Cell Carcinoma , 2017, Journal of Cancer.

[13]  Kyoung-Jin Oh,et al.  Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines , 2016, International journal of molecular sciences.

[14]  Y. Dong,et al.  Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer , 2016, Oncotarget.

[15]  G. Weber.  Time and Circumstances: Cancer Cell Metabolism at Various Stages of Disease Progression , 2016, Front. Oncol..

[16]  Ming Li,et al.  Circulating Tumor Cells: A New Window for Diagnosis and Evaluation of Cancer. , 2016, Anti-cancer agents in medicinal chemistry.

[17]  K. Tabata,et al.  Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer , 2016, International journal of molecular sciences.

[18]  G. Weber.  Metabolism in cancer metastasis , 2016, International journal of cancer.

[19]  Klaus Pantel,et al.  Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. , 2016, Cancer discovery.

[20]  L. Niu,et al.  Delta-like 1homolog in Capra hircus: molecular characteristics, expression pattern and phylogeny , 2016, Molecular Biology Reports.

[21]  L. Terracciano,et al.  Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis , 2016, Oncotarget.

[22]  J. Yu,et al.  Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response. , 2015, World journal of gastroenterology.

[23]  C. Cordon-Cardo,et al.  Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. , 2015, Journal of visualized experiments : JoVE.

[24]  G. Mælandsmo,et al.  Metabolic reprogramming supports the invasive phenotype in malignant melanoma. , 2015, Cancer letters.

[25]  H. Jang,et al.  Core Pluripotency Factors Directly Regulate Metabolism in Embryonic Stem Cell to Maintain Pluripotency , 2015, Stem cells.

[26]  Jie Yuan,et al.  Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways , 2015, Oncotarget.

[27]  Eshel Ben-Jacob,et al.  Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis , 2015, Front. Oncol..

[28]  Hong Wu,et al.  Tracking and Functional Characterization of Epithelial-Mesenchymal Transition and Mesenchymal Tumor Cells during Prostate Cancer Metastasis. , 2015, Cancer research.

[29]  N. Yang,et al.  Classification of Circulating Tumor Cells by Epithelial-Mesenchymal Transition Markers , 2015, PloS one.

[30]  Zongwei Li,et al.  Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling. , 2014, Cellular signalling.

[31]  Mahmood Ayub,et al.  Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer , 2014, Nature Medicine.

[32]  E. Cuyás,et al.  The nutritional phenome of EMT-induced cancer stem-like cells , 2014, Oncotarget.

[33]  H. Northoff,et al.  Phosphoglycerate kinase 1 as a promoter of metastasis in colon cancer. , 2013, International journal of oncology.

[34]  Sridhar Ramaswamy,et al.  Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.

[35]  Adrian L Harris,et al.  Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. , 2012, Cell metabolism.

[36]  Hao Hu,et al.  Overexpression of G6PD is associated with poor clinical outcome in gastric cancer. , 2012 .

[37]  Ming Tan,et al.  Glucose Oxidation Modulates Anoikis and Tumor Metastasis , 2012, Molecular and Cellular Biology.

[38]  J. Dinman.  Control of gene expression by translational recoding , 2012, Advances in Protein Chemistry and Structural Biology.

[39]  K. Aldape,et al.  Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation , 2011, Nature.

[40]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[41]  Jane E. Visvader,et al.  Cells of origin in cancer , 2011, Nature.

[42]  P. Hamar,et al.  Post-transcriptional gene-expression regulation by micro RNA (miRNA) network in renal disease. , 2010, Advanced drug delivery reviews.

[43]  Franziska Michor,et al.  The Origins and Implications of Intratumor Heterogeneity , 2010, Cancer Prevention Research.

[44]  L. Fink,et al.  Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors , 2009, Cancer Epidemiology Biomarkers & Prevention.

[45]  Hui Jiang,et al.  How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. , 2008, Acta biochimica et biophysica Sinica.

[46]  William Ho,et al.  Integrated analytic hierarchy process and its applications - A literature review , 2008, Eur. J. Oper. Res..

[47]  H. Northoff,et al.  Phosphoglycerate Kinase 1 Promoting Tumor Progression and Metastasis in Gastric Cancer - Detected in a Tumor Mouse Model Using Positron Emission Tomography/Magnetic Resonance Imaging , 2006, Cellular Physiology and Biochemistry.

[48]  N. Socci,et al.  Gastrointestinal Stromal Tumors in Children and Young Adults: A Clinicopathologic, Molecular, and Genomic Study of 15 Cases and Review of the Literature , 2005, Journal of pediatric hematology/oncology.

[49]  W. J. Allard,et al.  Circulating tumor cells predict survival in patients with metastatic prostate cancer. , 2005, Urology.

[50]  J. Horst,et al.  Expression of two protein isoforms of PAX7 is controlled by competing cleavage-polyadenylation and splicing. , 2004, Gene.

[51]  A. Shaaban,et al.  Wild-type oestrogen receptor beta (ERβ1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers , 2004, British Journal of Cancer.

[52]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[53]  David E. Misek,et al.  Discordant Protein and mRNA Expression in Lung Adenocarcinomas * , 2002, Molecular & Cellular Proteomics.

[54]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[55]  J. Zheng,et al.  [Isolation and characterization of human prostate cancer cell subclones with different metastatic potential]. , 1999, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[56]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[57]  D. Paulson,et al.  Isolation of a human prostate carcinoma cell line (DU 145) , 1978, International journal of cancer.

[58]  T. L. Saaty.  A Scaling Method for Priorities in Hierarchical Structures , 1977 .

[59]  Botao Zhao,et al.  miR-143 inhibits cell proliferation by targeting autophagy-related 2B in non-small cell lung cancer H1299 cells. , 2015, Molecular medicine reports.

[60]  J. Ge,et al.  Overexpression of G6PD is associated with poor clinical outcome in gastric cancer , 2012, Tumor Biology.

[61]  I. Galante Romo,et al.  Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation. , 2010, Archivos espanoles de urologia.

[62]  I. G. Romo,et al.  Cuantificación inmunomagnética de células tumorales circulantes en pacientes con cáncer de próstata: correlación clínica y patológica , 2010 .

[63]  Qing‐Yu He,et al.  Mammary serine protease inhibitor inhibits epithelial growth factor‐induced epithelial‐mesenchymal transition of esophageal carcinoma cells , 2009, Cancer.

[64]  R. W. Saaty,et al.  The analytic hierarchy process—what it is and how it is used , 1987 .

[65]  S. Arya,et al.  The LNCaP cell line--a new model for studies on human prostatic carcinoma. , 1980, Progress in clinical and biological research.